OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+8.8%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$95M
AUM Growth
+$95M
(-6.5%)
Cap. Flow
-$5.81M
Cap. Flow
% of AUM
-6.11%
Top 10 Holdings %
Top 10 Hldgs %
53.5%
Holding
63
New
2
Increased
1
Reduced
29
Closed
2
Top Buys
| 1 |
iShares Biotechnology ETF
IBB
|
$2.67M |
| 2 |
ProQR Therapeutics
PRQR
|
$992K |
| 3 |
FibroGen
FGEN
|
$210K |
Top Sells
| 1 |
Direxion Daily S&P Biotech Bull 3X Shares
LABU
|
$1.37M |
| 2 |
Nektar Therapeutics
NKTR
|
$732K |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$558K |
| 4 |
Neurocrine Biosciences
NBIX
|
$422K |
| 5 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
$417K |
Sector Composition
| 1 | Healthcare | 80.2% |
| 2 | Real Estate | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| $7.32M | 6.33% | 130,500 | – | – |
|
2
SPDR S&P Biotech ETF
XBI
$5.07B
| $5.52M | 4.77% | 65,000 | – | – |
|
3
Bristol-Myers Squibb
BMY
$96B
| $5.52M | 4.77% | 90,000 | – | – |
|
|
4
Nektar Therapeutics
NKTR
$568M
| $5.5M | 4.76% | 92,070 -12,258 | -12% | -$732K |
|
|
5
Alnylam Pharmaceuticals
ALNY
$58.5B
| $5.47M | 4.73% | 43,064 -4,395 | -9% | -$558K |
|
6
Merck
MRK
$210B
| $4.71M | 4.07% | 83,700 | – | – |
|
|
RXDX
7
DELISTED
Ignyta, Inc.
RXDX
| $4.55M | 3.94% | 170,500 | – | – |
|
8
AstraZeneca
AZN
$248B
| $4.16M | 3.6% | 120,000 | – | – |
|
9
Pfizer
PFE
$141B
| $4.07M | 3.52% | 112,300 | – | – |
|
|
10
iShares Biotechnology ETF
IBB
$5.6B
| $4M | 3.46% | 37,500 +25,000 | +200% | +$2.67M |
|
11
Vertex Pharmaceuticals
VRTX
$100B
| $2.49M | 2.16% | 16,639 -1,635 | -9% | -$245K |
|
12
Alkermes
ALKS
$4.78B
| $2.4M | 2.07% | 43,763 -4,481 | -9% | -$245K |
|
13
Mettler-Toledo International
MTD
$26.8B
| $2.23M | 1.93% | 3,594 | – | – |
|
14
GSK
GSK
$79.9B
| $2.13M | 1.84% | 60,000 | – | – |
|
15
Illumina
ILMN
$15.8B
| $2.12M | 1.84% | 9,717 -1,518 | -14% | -$332K |
|
16
Ionis Pharmaceuticals
IONS
$6.79B
| $1.98M | 1.71% | 39,388 -4,795 | -11% | -$241K |
|
|
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.91M | 1.65% | 35,668 -5,595 | -14% | -$299K |
|
18
Biogen
BIIB
$19.4B
| $1.85M | 1.6% | 5,793 -894 | -13% | -$285K |
|
19
Qiagen
QGEN
$10.1B
| $1.75M | 1.51% | 56,445 -7,976 | -12% | -$247K |
|
20
Incyte
INCY
$16.5B
| $1.74M | 1.5% | 18,318 -1,830 | -9% | -$173K |
|
21
Amgen
AMGN
$155B
| $1.73M | 1.49% | 9,924 -1,482 | -13% | -$258K |
|
22
Agios Pharmaceuticals
AGIO
$2.19B
| $1.64M | 1.42% | 28,704 -4,643 | -14% | -$265K |
|
23
Regeneron Pharmaceuticals
REGN
$61.5B
| $1.53M | 1.33% | 4,076 -485 | -11% | -$182K |
|
24
BioMarin Pharmaceuticals
BMRN
$11.2B
| $1.53M | 1.32% | 17,118 -2,808 | -14% | -$250K |
|
|
CELG
25
DELISTED
Celgene Corp
CELG
| $1.52M | 1.31% | 14,540 -1,637 | -10% | -$171K |
|